Workflow
Enzyme therapies
icon
Search documents
BioMarin Pharmaceutical(BMRN) - 2025 Q2 - Earnings Call Transcript
2025-08-04 21:30
Financial Data and Key Metrics Changes - Total revenues grew 16% in Q2 2025 and 15% year over year compared to the same periods in 2024, driven by strong global demand and new patient starts [12][18] - Non-GAAP diluted earnings per share increased to $1.44, reflecting a growth rate more than three times that of revenue growth [17] - Operating cash flow reached $185 million in Q2, a 55% increase compared to the same period in 2024 [18] Business Line Data and Key Metrics Changes - VOXZOGO revenue increased 20% year over year to $221 million, supported by global expansion and new patient starts [12][20] - Enzyme Therapies revenue rose 15% year over year to $555 million, with Palynziq and Vimizim contributing significantly to growth [14][28] - Rocadian revenue was $9 million in Q2, primarily from the U.S. and Italy [14] Market Data and Key Metrics Changes - The company expects second half VOXZOGO revenue to be higher than the first half, with a full year target of $900 million to $935 million [13][14] - The company anticipates continued strong growth throughout the remainder of 2025, leading to an increase in full year guidance for total revenues [9][19] Company Strategy and Development Direction - The company plans to advance BMN 333, a long-acting therapy for achondroplasia, to a registrational Phase 2/3 study in the first half of 2026 [7][31] - The acquisition of Inozyme broadens the enzyme therapies portfolio, with BMN 401 expected to address ENPP1 deficiency [8][35] - The company aims to diversify its growth strategy through strategic business development transactions [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver strong growth and value creation for stakeholders through 2025 and beyond [10][19] - The management highlighted the importance of patient adherence and support programs to maintain high compliance rates [66][68] Other Important Information - The company expects to account for the Inozyme acquisition as an asset purchase, impacting financial results in 2025 [19] - The company is on track to submit applications for Palynziq to include adolescents in the U.S. and EU in the second half of 2025 [32] Q&A Session Summary Question: Clarification on BMN 333 and safety profile - Management confirmed that the agent referred to is TransCon CNP and stated that no unexpected safety issues have been observed in the healthy volunteer study [39][40] Question: Thoughts on competitive landscape for achondroplasia - Management noted that while early data shows growth hormone combinations may provide short-term increases, long-term benefits remain uncertain [44][45] Question: Contributions to VOXZOGO guidance - Management explained that the adjustment in guidance is due to order timing and a better understanding of trends as the year progresses [48][50] Question: Update on ITC proceedings - Management expects initial determination from the ITC on June 8, 2026, with a completion date targeted for October 8, 2026 [53][54] Question: Details on BMN 333 superiority trial design - Management refrained from providing specific details on powering but expressed confidence in the biological hypothesis being tested [56][58] Question: Update on hypochondroplasia and patient enrollment - Management emphasized the importance of early diagnosis and treatment for hypochondroplasia, leveraging existing relationships to raise awareness [100][101]